Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Neratinib for Breast Cancer
Recruiting3 awardsPhase 2
Germantown, Tennessee
This trial tests a treatment for early-stage triple-negative breast cancer patients with abnormal HER2 signaling. The treatment starts with neratinib, a drug that blocks cancer growth signals, followed by a combination of neratinib and two chemotherapy drugs, paclitaxel and carboplatin. The goal is to see if this approach leads to better outcomes than standard treatments.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service